Hauptseite > Publikationsdatenbank > Diagnostic potential of PET/CT using a $^{68}$Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience > print

001     824545
005     20210129225050.0
024 7 _ |a 10.1007/s00259-016-3360-2
|2 doi
024 7 _ |a 0340-6997
|2 ISSN
024 7 _ |a 1432-105X
|2 ISSN
024 7 _ |a 1619-7070
|2 ISSN
024 7 _ |a 1619-7089
|2 ISSN
024 7 _ |a WOS:000389242200013
|2 WOS
024 7 _ |a altmetric:6260303
|2 altmetric
024 7 _ |a pmid:26996777
|2 pmid
037 _ _ |a FZJ-2016-07117
082 _ _ |a 610
100 1 _ |0 P:(DE-HGF)0
|a Sawicki, Lino M.
|b 0
|e Corresponding author
245 _ _ |a Diagnostic potential of PET/CT using a $^{68}$Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience
260 _ _ |a Heidelberg [u.a.]
|b Springer-Verl.
|c 2017
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1482130370_5861
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
520 _ _ |a Purpose To evaluate the diagnostic potential of whole-bodyPET/CT using a 68Ga-labelled PSMA ligand in renal cell carcinoma(RCC).Methods Six patients with histopathologically proven RCCunderwent 68Ga-PSMA PET/CT. Each PET/CT scan wasevaluated in relation to lesion count, location and dignity.SUVmax was measured in primary tumours and PETpositivemetastases. Tumour-to-background SUVmax ratios(TBRSUVmax) were calculated for primary RCCs in relationto the surrounding normal renal parenchyma. Metastasis-tobackgroundSUVmax ratios (MBRSUVmax) were calculatedfor PET-positive metastases in relation to gluteal muscle.Results Five primary RCCs and 16 metastases were evaluated.The mean SUVmax of the primary RCCs was 9.9 ± 9.2(range 1.7 – 27.2). Due to high uptake in the surrounding renalparenchyma, the mean TBRSUVmax of the primary RCCs wasonly 0.2 ± 0.3 (range 0.02 – 0.7). Eight metastases showed focal68Ga-PSMA uptake (SUVmax 9.9 ± 8.3, range 3.4 – 25.6).The mean MBRSUVmax of these PET-positive metastases was11.7 ± 0.2 (range 4.4 – 28.1). All PET-negative metastaseswere subcentimetre lung metastases.Conclusion 68Ga-PSMA PET/CT appears to be a promisingmethod for detecting RCC metastases. However, no additionaldiagnostic value in assessing the primary tumour was found.
536 _ _ |0 G:(DE-HGF)POF3-572
|a 572 - (Dys-)function and Plasticity (POF3-572)
|c POF3-572
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |0 P:(DE-HGF)0
|a Buchbender, Christian
|b 1
700 1 _ |0 P:(DE-HGF)0
|a Boos, Johannes
|b 2
700 1 _ |0 P:(DE-HGF)0
|a Giessing, Markus
|b 3
700 1 _ |0 P:(DE-Juel1)131818
|a Ermert, Johannes
|b 4
|u fzj
700 1 _ |0 P:(DE-HGF)0
|a Antke, Christina
|b 5
700 1 _ |0 P:(DE-HGF)0
|a Antoch, Gerald
|b 6
700 1 _ |0 P:(DE-Juel1)132313
|a Hautzel, Hubertus
|b 7
|u fzj
773 _ _ |0 PERI:(DE-600)2098375-X
|a 10.1007/s00259-016-3360-2
|g Vol. 44, no. 1, p. 102 - 107
|n 1
|p 102 - 107
|t European journal of nuclear medicine and molecular imaging
|v 44
|x 1619-7089
|y 2017
856 4 _ |u https://juser.fz-juelich.de/record/824545/files/art_10.1007_s00259-016-3360-2.pdf
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/824545/files/art_10.1007_s00259-016-3360-2.gif?subformat=icon
|x icon
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/824545/files/art_10.1007_s00259-016-3360-2.jpg?subformat=icon-1440
|x icon-1440
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/824545/files/art_10.1007_s00259-016-3360-2.jpg?subformat=icon-180
|x icon-180
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/824545/files/art_10.1007_s00259-016-3360-2.jpg?subformat=icon-640
|x icon-640
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/824545/files/art_10.1007_s00259-016-3360-2.pdf?subformat=pdfa
|x pdfa
|y Restricted
909 C O |o oai:juser.fz-juelich.de:824545
|p VDB
910 1 _ |0 I:(DE-588b)5008462-8
|6 P:(DE-Juel1)131818
|a Forschungszentrum Jülich
|b 4
|k FZJ
910 1 _ |0 I:(DE-588b)5008462-8
|6 P:(DE-Juel1)132313
|a Forschungszentrum Jülich
|b 7
|k FZJ
913 1 _ |0 G:(DE-HGF)POF3-572
|1 G:(DE-HGF)POF3-570
|2 G:(DE-HGF)POF3-500
|a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|v (Dys-)function and Plasticity
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2017
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
915 _ _ |0 StatID:(DE-HGF)0310
|2 StatID
|a DBCoverage
|b NCBI Molecular Biology Database
915 _ _ |0 StatID:(DE-HGF)0600
|2 StatID
|a DBCoverage
|b Ebsco Academic Search
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b ASC
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b EUR J NUCL MED MOL I : 2015
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Thomson Reuters Master Journal List
915 _ _ |0 StatID:(DE-HGF)0110
|2 StatID
|a WoS
|b Science Citation Index
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
915 _ _ |0 StatID:(DE-HGF)0111
|2 StatID
|a WoS
|b Science Citation Index Expanded
915 _ _ |0 StatID:(DE-HGF)1110
|2 StatID
|a DBCoverage
|b Current Contents - Clinical Medicine
915 _ _ |0 StatID:(DE-HGF)1030
|2 StatID
|a DBCoverage
|b Current Contents - Life Sciences
915 _ _ |0 StatID:(DE-HGF)9905
|2 StatID
|a IF >= 5
|b EUR J NUCL MED MOL I : 2015
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-5-20090406
|k INM-5
|l Nuklearchemie
|x 0
920 1 _ |0 I:(DE-Juel1)VDB145
|k KME
|l Klinisch-Medizinische Einrichtungen (Univ. Düsseldorf)
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)INM-5-20090406
980 _ _ |a I:(DE-Juel1)VDB145
980 _ _ |a UNRESTRICTED
981 _ _ |a I:(DE-Juel1)VDB145

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21